Section 1: Identification

Product name: Fidaxomicin Solid Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand
Telephone: +1-908-740-4000
Emergency telephone number: +1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

Section 2: Hazard identification

GHS Classification
Acute toxicity (Oral): Category 4

GHS label elements
Hazard pictograms:

Signal word: Warning
Hazard statements: H302 Harmful if swallowed.
Precautionary statements:
Prevention:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.
SAFETY DATA SHEET

Fidaxomicin Solid Formulation

Section 3: Composition/information on ingredients

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mixture</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fidaxomicin</td>
<td>873857-62-6</td>
<td>&gt;= 30 - &lt; 60</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>&gt;= 10 - &lt; 30</td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td>532-32-1</td>
<td>&lt; 10</td>
</tr>
<tr>
<td>Citric acid</td>
<td>77-92-9</td>
<td>&lt; 10</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact: Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed: If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed: Harmful if swallowed. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Metal oxides
Chlorine compounds

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

**Section 6: Accidental release measures**

| Personal precautions, protective equipment and emergency procedures | Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

**Section 7: Handling and storage**

| Technical measures | Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | Use only with adequate ventilation. |
| Advice on safe handling | Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the

| 3 / 16 |
Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fidaxomicin</td>
<td>873857-62-6</td>
<td>TWA</td>
<td>200 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>WES-TWA</td>
<td>10 mg/m³</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

Engineering measures: Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection Material: Chemical-resistant gloves

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a facemask or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.

Section 9: Physical and chemical properties

Appearance: granules
SAFETY DATA SHEET
Fidaxomicin Solid Formulation

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colour</td>
<td>White to light yellow</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>Water solubility</td>
</tr>
<tr>
<td></td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Viscosity, kinematic</td>
</tr>
<tr>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>No data available</td>
</tr>
</tbody>
</table>
Fidaxomicin Solid Formulation

Section 10: Stability and reactivity

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions:
- May form explosive dust-air mixture during processing, handling or other means.
- Can react with strong oxidizing agents.

Conditions to avoid:
- Heat, flames and sparks.
- Avoid dust formation.

Incompatible materials:
- Oxidizing agents

Hazardous decomposition products:
- No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity:
Harmful if swallowed.

Product:
Acute oral toxicity:
- Acute toxicity estimate: 875.04 mg/kg
  Method: Calculation method

Components:

Fidaxomicin:
Acute oral toxicity:
- LD50 (Rat): > 1,000 mg/kg
  LD50 (Dog): > 120 mg/kg

Acute toxicity (other routes of administration):
- LD50 (Rat): 200 mg/kg
  Application Route: Intravenous

Cellulose:
Acute oral toxicity:
- LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity:
- LC50 (Rat): > 5.8 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist

Acute dermal toxicity:
- LD50 (Rabbit): > 2,000 mg/kg

Sodium benzoate:
Acute oral toxicity:
- LD50 (Rat): > 2,000 mg/kg
  Assessment: The substance or mixture has no acute oral toxicity
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Citric acid:
Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation
Not classified based on available information.

Components:

Sodium benzoate:
Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Citric acid:
Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Sodium benzoate:
Species : Rabbit
Result : Irritation to eyes, reversing within 21 days
Method : OECD Test Guideline 405

Citric acid:
Species : Rabbit
Result : Irritation to eyes, reversing within 21 days
Method : OECD Test Guideline 405

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.
Components:

**Sodium benzoate:**

- **Test Type:** Local lymph node assay (LLNA)
- **Exposure routes:** Skin contact
- **Species:** Mouse
- **Result:** negative
- **Remarks:** Based on data from similar materials

Chronic toxicity

Germ cell mutagenicity

Not classified based on available information.

Components:

**Fidaxomicin:**

- **Genotoxicity in vitro:**
  - Test Type: Bacterial reverse mutation assay (AMES)
    - Result: negative
  - Test Type: Chromosome aberration test in vitro
    - Test system: Chinese hamster ovary cells
    - Result: positive

- **Genotoxicity in vivo:**
  - Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
    - Species: Rat
    - Application Route: Intravenous
    - Result: negative

  
  Test Type: comet assay
  - Species: Rat
  - Result: negative

**Cellulose:**

- **Genotoxicity in vitro:**
  - Test Type: Bacterial reverse mutation assay (AMES)
    - Result: negative

  Test Type: In vitro mammalian cell gene mutation test
  - Result: negative

- **Genotoxicity in vivo:**
  - Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
    - Species: Mouse
    - Application Route: Ingestion
    - Result: negative

**Sodium benzoate:**

- **Genotoxicity in vitro:**
  - Test Type: Bacterial reverse mutation assay (AMES)
    - Result: negative

  Test Type: Chromosome aberration test in vitro
  - Result: positive
Genotoxicity in vivo: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Citric acid:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: in vitro micronucleus test
Result: positive
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity
Not classified based on available information.

Components:
Cellulose:
Species: Rat
Application Route: Ingestion
Exposure time: 72 weeks
Result: negative

Sodium benzoate:
Species: Rat
Application Route: Ingestion
Exposure time: 24 month(s)
Result: negative

Reproductive toxicity
Not classified based on available information.

Components:
Fidaxomicin:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Intravenous injection
Fertility: NOAEL: 6.3 mg/kg body weight

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 12.6 mg/kg body weight
Remarks: No significant adverse effects were reported

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 7 mg/kg body weight
Remarks: No significant adverse effects were reported

**Cellulose:**

**Effects on fertility**
- Test Type: One-generation reproduction toxicity study
- Species: Rat
- Application Route: Ingestion
- Result: negative

**Effects on foetal development**
- Test Type: Fertility/early embryonic development
- Species: Rat
- Application Route: Ingestion
- Result: negative

**Sodium benzoate:**

**Effects on fertility**
- Test Type: Four-generation reproduction toxicity study
- Species: Rat
- Application Route: Ingestion
- Result: negative
  - Remarks: Based on data from similar materials

**Effects on foetal development**
- Test Type: Embryo-foetal development
- Species: Rat
- Application Route: Ingestion
- Result: negative

**Citric acid:**

**Effects on foetal development**
- Test Type: One-generation reproduction toxicity study
- Species: Rat
- Application Route: Ingestion
- Result: negative

**STOT - single exposure**
Not classified based on available information.

**STOT - repeated exposure**
Not classified based on available information.

**Repeated dose toxicity**

**Components:**

**Fidaxomicin:**
- Species: Rat
- NOAEL: 90 mg/kg
- Application Route: Oral
Exposure time: 28 D  
Remarks: No significant adverse effects were reported

Species: Rat  
NOAEL: 62.5 mg/kg  
Application Route: Intravenous  
Exposure time: 14 D

Species: Dog  
NOAEL: 9,600 mg/kg  
Application Route: Oral  
Exposure time: 3 M  
Symptoms: Vomiting  
Remarks: No significant adverse effects were reported

Species: Monkey  
NOAEL: 90 mg/kg  
Application Route: Oral  
Exposure time: 28 D  
Remarks: No significant adverse effects were reported

Species: Juvenile rat  
NOAEL: 200 mg/kg  
Application Route: Oral  
Exposure time: 28 D  
Remarks: No significant adverse effects were reported

**Cellulose:**
Species: Rat  
NOAEL: >= 9,000 mg/kg  
Application Route: Ingestion  
Exposure time: 90 Days

**Sodium benzoate:**
Species: Rat  
NOAEL: 1,000 mg/kg  
Application Route: Ingestion  
Exposure time: 24 Months

**Citric acid:**
Species: Rat  
NOAEL: 4,000 mg/kg  
LOAEL: 8,000 mg/kg  
Application Route: Ingestion  
Exposure time: 10 Days

**Aspiration toxicity**
Not classified based on available information.
Experience with human exposure

Components:

Fidaxomicin:
Ingestion: Symptoms: Abdominal pain, Nausea, Vomiting, constipation

Section 12: Ecological information

Ecotoxicity

Components:

Fidaxomicin:
Toxicity to algae/aquatic plants: EC50 (Anabaena flos-aquae (cyanobacterium)): > 18.4 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Anabaena flos-aquae (cyanobacterium)): 5.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity):
NOEC (Pimephales promelas (fathead minnow)): 8.91 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 19.6 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms:
EC50: > 50 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 5.9 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Cellulose:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Sodium benzoate:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): 484 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 96 h
Toxicity to algae/aquatic plants:
- EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201

- NOEC (Pseudokirchneriella subcapitata (green algae)): 32 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201

Citric acid:
Toxicity to fish:
- LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
  Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates:
- EC50 (Daphnia magna (Water flea)): 1,535 mg/l
  Exposure time: 24 h

Persistence and degradability

Components:

Cellulose:
Biodegradability:
- Result: Readily biodegradable.

Sodium benzoate:
Biodegradability:
- Result: Readily biodegradable.
  Biodegradation: 75%
  Exposure time: 28 d

Citric acid:
Biodegradability:
- Result: Readily biodegradable.
  Biodegradation: 97%
  Exposure time: 28 d
  Method: OECD Test Guideline 301B

Bioaccumulative potential

Components:

Fidaxomicin:
Partition coefficient: n-octanol/water:
- log Pow: 4.4

Sodium benzoate:
Partition coefficient: n-octanol/water:
- log Pow: 1.88

Citric acid:
Partition coefficient: n-octanol/water:
- log Pow: -1.72
Mobility in soil

Components:

Fidaxomicin:
Distribution among environmental compartments: log Koc: 0.80

Other adverse effects
No data available

Section 13: Disposal considerations

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG
UN number: Not applicable
Proper shipping name: Not applicable
Class: Not applicable
Subsidiary risk: Not applicable
Packing group: Not applicable
Labels: Not applicable

IATA-DGR
UN/ID No.: Not applicable
Proper shipping name: Not applicable
Class: Not applicable
Subsidiary risk: Not applicable
Packing group: Not applicable
Labels: Not applicable
Packing instruction (cargo aircraft): Not applicable
Packing instruction (passenger aircraft): Not applicable

IMDG-Code
UN number: Not applicable
Proper shipping name: Not applicable
Class: Not applicable
Subsidiary risk: Not applicable
Packing group: Not applicable
Labels: Not applicable
EmS Code: Not applicable
Marine pollutant: Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.
Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number
HSR100425 Pharmaceutical Active Ingredients Group Standard 2017

HSW Controls
Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

Section 16: Other information

Further information

Date format : dd.mm.yyyy

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average
NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average
Safety Data Sheet

Fidaxomicin Solid Formulation

Version 1.3
Revision Date: 27.08.2021
SDS Number: 4750800-00004
Date of last issue: 09.04.2021
Date of first issue: 15.08.2019

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NZ / EN